Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia.

Krauss AC, Gao X, Li L, Manning ML, Patel P, Fu W, Janoria KG, Gieser G, Bateman DA, Przepiorka D, Shen YL, Shord SS, Sheth CM, Banerjee A, Liu J, Goldberg KB, Farrell AT, Blumenthal GM, Pazdur R.

Clin Cancer Res. 2019 May 1;25(9):2685-2690. doi: 10.1158/1078-0432.CCR-18-2990. Epub 2018 Dec 12.

PMID:
30541745
2.

FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation.

Oneal PA, Kwitkowski V, Luo L, Shen YL, Subramaniam S, Shord S, Goldberg KB, McKee AE, Kaminskas E, Farrell A, Pazdur R.

Oncologist. 2018 Dec;23(12):1520-1524. doi: 10.1634/theoncologist.2018-0295. Epub 2018 Aug 17.

3.

FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.

Kasamon YL, Ko CW, Subramaniam S, Ma L, Yang Y, Nie L, Shord S, Przepiorka D, Farrell AT, McKee AE, Pazdur R.

Oncologist. 2018 Dec;23(12):1511-1519. doi: 10.1634/theoncologist.2018-0222. Epub 2018 Aug 16.

4.

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.

Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, Przepiorka D, Farrell AT, Pazdur R.

Oncologist. 2018 Aug;23(8):943-947. doi: 10.1634/theoncologist.2018-0028. Epub 2018 Apr 5.

5.

FDA Approval Summary: Sonidegib-Response.

Shord SS, Casey D, Zhao H, Demko S, Keegan P, Pazdur R.

Clin Cancer Res. 2017 Oct 1;23(19):5994. doi: 10.1158/1078-0432.CCR-17-2135. No abstract available.

6.

The Role of Clinical Pharmacology in Oncology Dose Selection: Advances and Opportunities in Personalized Medicine.

Shord SS.

J Clin Pharmacol. 2017 Oct;57 Suppl 10:S99-S104. doi: 10.1002/jcph.922. No abstract available.

PMID:
28921640
7.

FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.

Bhatnagar V, Gormley NJ, Luo L, Shen YL, Sridhara R, Subramaniam S, Shen G, Ma L, Shord S, Goldberg KB, Farrell AT, McKee AE, Pazdur R.

Oncologist. 2017 Nov;22(11):1347-1353. doi: 10.1634/theoncologist.2017-0229. Epub 2017 Sep 13.

8.

FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma.

Casey D, Demko S, Shord S, Zhao H, Chen H, He K, Putman A, Helms W, Keegan P, Pazdur R.

Clin Cancer Res. 2017 May 15;23(10):2377-2381. doi: 10.1158/1078-0432.CCR-16-2051. Epub 2017 Jan 10.

9.

FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib.

Larkins E, Blumenthal GM, Chen H, He K, Agarwal R, Gieser G, Stephens O, Zahalka E, Ringgold K, Helms W, Shord S, Yu J, Zhao H, Davis G, McKee AE, Keegan P, Pazdur R.

Clin Cancer Res. 2016 Nov 1;22(21):5171-5176. Epub 2016 Jul 13.

10.

FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma.

Miller BW, Przepiorka D, de Claro RA, Lee K, Nie L, Simpson N, Gudi R, Saber H, Shord S, Bullock J, Marathe D, Mehrotra N, Hsieh LS, Ghosh D, Brown J, Kane RC, Justice R, Kaminskas E, Farrell AT, Pazdur R.

Clin Cancer Res. 2015 Apr 1;21(7):1525-9. doi: 10.1158/1078-0432.CCR-14-2522. Epub 2015 Feb 2.

11.

Epigenetics and oncology.

Mummaneni P, Shord SS.

Pharmacotherapy. 2014 May;34(5):495-505. doi: 10.1002/phar.1408. Epub 2014 Mar 11. Review.

PMID:
24619798
12.

Are hepatic impairment studies necessary for therapeutic proteins?

Yang J, Shord S, Zhao H, Men Y, Rahman A.

Clin Ther. 2013 Sep;35(9):1444-51. doi: 10.1016/j.clinthera.2013.06.010. Epub 2013 Jul 26.

PMID:
23891362
13.

Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper.

Gorovits B, Alley SC, Bilic S, Booth B, Kaur S, Oldfield P, Purushothama S, Rao C, Shord S, Siguenza P.

Bioanalysis. 2013 May;5(9):997-1006. doi: 10.4155/bio.13.38.

14.

Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.

Cohen MH, Chen H, Shord S, Fuchs C, He K, Zhao H, Sickafuse S, Keegan P, Pazdur R.

Oncologist. 2013;18(4):460-6. doi: 10.1634/theoncologist.2012-0458. Epub 2013 Apr 10.

15.

Desired professional development pathways for clinical pharmacists.

American College of Clinical Pharmacy, Shord SS, Schwinghammer TL, Badowski M, Banderas J, Burton ME, Chapleau CA, Gallagher JC, Matsuura G, Parli SE, Yunker N.

Pharmacotherapy. 2013 Apr;33(4):e34-42. doi: 10.1002/phar.1251. Epub 2013 Feb 11.

PMID:
23401084
16.

Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a "physician's choice" control arm in a randomized approval trial.

Donoghue M, Lemery SJ, Yuan W, He K, Sridhara R, Shord S, Zhao H, Marathe A, Kotch L, Jee J, Wang Y, Zhou L, Adams WM, Jarral V, Pilaro A, Lostritto R, Gootenberg JE, Keegan P, Pazdur R.

Clin Cancer Res. 2012 Mar 15;18(6):1496-505. doi: 10.1158/1078-0432.CCR-11-2149. Epub 2012 Jan 26.

17.

The interactions of anti-cancer drugs approved in the last decade in the United States with membrane transporters.

Jain L, Abraham S, Shord SS.

Anticancer Agents Med Chem. 2010 Oct 1;10(8):601-16. Review.

PMID:
21194401
18.

Optimizing chemotherapy: concomitant medication lists.

Hanigan MH, Dela Cruz BL, Shord SS, Medina PJ, Fazili J, Thompson DM.

Clin Pharmacol Ther. 2011 Jan;89(1):114-9. doi: 10.1038/clpt.2010.253. Epub 2010 Dec 1.

19.

Transfusions increase with nationally driven reimbursement changes of erythropoiesis stimulating agents for chemotherapy-induced anemia.

Yu JM, Shord SS, Cuellar S.

J Oncol Pharm Pract. 2011 Dec;17(4):360-5. doi: 10.1177/1078155210382318. Epub 2010 Sep 8.

PMID:
20826550
20.

Fukinolic acid derivatives and triterpene glycosides from black cohosh inhibit CYP isozymes, but are not cytotoxic to Hep-G2 cells in vitro.

Huang Y, Jiang B, Nuntanakorn P, Kennelly EJ, Shord S, Lawal TO, Mahady GB.

Curr Drug Saf. 2010 Apr;5(2):118-24.

21.

Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam.

Shord SS, Chan LN, Camp JR, Vasquez EM, Jeong HY, Molokie RE, Baum CL, Xie H.

Br J Clin Pharmacol. 2010 Feb;69(2):160-6. doi: 10.1111/j.1365-2125.2009.03559.x.

22.

Drug-botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals.

Shord SS, Shah K, Lukose A.

Integr Cancer Ther. 2009 Sep;8(3):208-27. doi: 10.1177/1534735409340900. Review.

PMID:
19815591
23.

Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen.

Beri R, Chunduri S, Sweiss K, Peace DJ, Mactal-Haaf C, Dobogai LC, Shord S, Quigley JG, Chen YH, Mahmud N, Rondelli D.

Bone Marrow Transplant. 2010 Feb;45(2):249-53. doi: 10.1038/bmt.2009.133. Epub 2009 Jun 22.

PMID:
19543331
24.
25.

Understanding and managing the possible adverse effects associated with bevacizumab.

Shord SS, Bressler LR, Tierney LA, Cuellar S, George A.

Am J Health Syst Pharm. 2009 Jun 1;66(11):999-1013. doi: 10.2146/ajhp080455. Review.

PMID:
19451611
26.

Influence of cyclooxygenase-1 genotype on ex vivo aspirin response in patients at risk for stroke.

Momary KM, Shapiro NL, Brace LD, Shord SS, Grossi E, Viana MA, Helgason CM, Nutescu EA, Cavallari LH.

Cerebrovasc Dis. 2009;27(6):585-93. doi: 10.1159/000214223. Epub 2009 Apr 24.

PMID:
19390185
27.

The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease.

Shord SS, Cavallari LH, Gao W, Jeong HY, Deyo K, Patel SR, Camp JR, Labott SM, Molokie RE.

Eur J Clin Pharmacol. 2009 Jul;65(7):651-8. doi: 10.1007/s00228-009-0646-3. Epub 2009 Apr 9.

28.

Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.

Campara M, Shord SS, Haaf CM.

J Clin Pharm Ther. 2009 Apr;34(2):207-13. doi: 10.1111/j.1365-2710.2008.00994.x.

PMID:
19250141
29.

Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes.

Sahi J, Shord SS, Lindley C, Ferguson S, LeCluyse EL.

J Biochem Mol Toxicol. 2009 Jan-Feb;23(1):43-58. doi: 10.1002/jbt.20264.

PMID:
19202563
30.

Evaluation of the Modified Diet in Renal Disease equation for calculation of carboplatin dose.

Shord SS, Bressler LR, Radhakrishnan L, Chen N, Villano JL.

Ann Pharmacother. 2009 Feb;43(2):235-41. doi: 10.1345/aph.1L446. Epub 2009 Feb 3.

PMID:
19193580
31.

Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature.

Sweiss KI, Beri R, Shord SS.

Drug Saf. 2008;31(11):989-96. Review.

PMID:
18840018
32.

Cytochrome P450 2C9 mediated metabolism in people with and without cancer.

Shord SS, Cavallari LH, Viana MA, Momary K, Neceskas J, Molokie RE, Deyo K, Patel SR.

Int J Clin Pharmacol Ther. 2008 Jul;46(7):365-74.

PMID:
18793590
33.

Chemotherapy-induced anemia at an urban academic medical center: iron studies and supplementation.

Shord SS, Cuellar S.

J Am Pharm Assoc (2003). 2008 Jul-Aug;48(4):487-93. doi: 10.1331/JAPhA.2008.07110.

PMID:
18653424
34.

Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia.

Shord SS, Hamilton JM Jr, Cuellar S.

J Oncol Pharm Pract. 2008 Mar;14(1):5-22. doi: 10.1177/1078155207087654. Review.

PMID:
18337436
35.

Examining differences in weekly warfarin dose in patients with and without cancer.

Grogan KM, Wong C, Nutescu EA, Shord SS.

Ther Drug Monit. 2007 Oct;29(5):638-43.

PMID:
17898656
36.

Evaluation of opioid induced nausea and vomiting in sickle cell disease.

Shord SS, Chew L, Villano J.

Am J Hematol. 2008 Mar;83(3):196-9.

37.

Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab.

Suen JK, Bressler L, Shord SS, Warso M, Villano JL.

Anticancer Drugs. 2007 Aug;18(7):827-9.

PMID:
17581306
38.

Intravenous administration of paclitaxel in Sprague-Dawley rats: what is a safe dose?

Shord SS, Camp JR.

Biopharm Drug Dispos. 2006 May;27(4):191-6.

PMID:
16566060
39.

Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer.

Shord SS, Thompson DM, Krempl GA, Hanigan MH.

Anticancer Drugs. 2006 Feb;17(2):207-15.

PMID:
16428940
40.
41.

A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.

Gillenwater HH, McCune JS, Lindley C, Faucette S, Shord S, Donahue A, Socinski MA, Stewart CF, Zamboni WC, Kirstein MN, Moore D.

Cancer Invest. 2005;23(6):511-9.

PMID:
16203659
42.

ET(B) receptor agonist, IRL 1620, does not affect paclitaxel plasma pharmacokinetics in breast tumour bearing rats.

Rai A, Rajeshkumar NV, Shord S, Gulati A.

J Pharm Pharmacol. 2005 Jul;57(7):869-76.

PMID:
15969946
43.

Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.

Lindley C, Goodin S, McCune J, Kane M, Amamoo MA, Shord S, Pham T, Yowell S, Laliberte K, Schell M, Bernard S, Socinski MA.

Am J Clin Oncol. 2005 Jun;28(3):270-6.

PMID:
15923800
44.

Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy.

Lindley C, Shea T, McCune J, Shord S, Decker J, Harvey D, Petros WP, Garbriel D, Serody J, Kirby S, Wiley J.

Anticancer Drugs. 2004 Jun;15(5):453-9.

PMID:
15166618
45.

Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy.

Treish I, Shord S, Valgus J, Harvey D, Nagy J, Stegal J, Lindley C.

Support Care Cancer. 2003 Aug;11(8):516-21. Epub 2003 Jun 27.

PMID:
12836088
46.

Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer.

Shord SS, Faucette SR, Gillenwater HH, Pescatore SL, Hawke RL, Socinski MA, Lindley C.

Cancer Chemother Pharmacol. 2003 Apr;51(4):328-36. Epub 2003 Mar 13.

PMID:
12721761
47.

Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.

Shord SS, Bernard SA, Lindley C, Blodgett A, Mehta V, Churchel MA, Poole M, Pescatore SL, Luo FR, Chaney SG.

Anticancer Res. 2002 Jul-Aug;22(4):2301-9.

PMID:
12174918
48.

The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes.

Lindley C, Hamilton G, McCune JS, Faucette S, Shord SS, Hawke RL, Wang H, Gilbert D, Jolley S, Yan B, LeCluyse EL.

Drug Metab Dispos. 2002 Jul;30(7):814-22.

PMID:
12065440
49.

Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation.

Faucette SR, Hawke RL, Shord SS, Lecluyse EL, Lindley CM.

Drug Metab Dispos. 2001 Aug;29(8):1123-9.

PMID:
11454731
50.

Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.

Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, Lindley CM.

Drug Metab Dispos. 2000 Oct;28(10):1222-30.

PMID:
10997944

Supplemental Content

Support Center